
Faze Medicines: A pioneering biotech company specializing in biomolecular condensate therapeutics.
Faze Medicines, founded with a mission to revolutionize the treatment of diseases through the science of biomolecular condensates, is a biotechnology company dedicated to developing innovative therapeutics. Their core vision is to harness the potential of biomolecular condensates to create novel treatments for a range of diseases, addressing unmet medical needs. Faze Medicines focuses on pioneering this groundbreaking science to offer new hope and effective solutions in the therapeutic market.
Notable figures affiliated with Faze Medicines include leading scientists and industry experts who bring extensive experience in biotechnology and drug development. The company has attracted significant investment from prominent venture capital firms, underscoring confidence in its innovative approach. Key achievements include advancing their research and development pipeline and establishing a strong intellectual property portfolio. Faze Medicines is poised to make a substantial impact on the biotech industry by translating cutting-edge science into life-changing therapies.

Dewpoint Therapeutics
dewpointx.com

ProFound Therapeutics
profoundtx.com

Transition Bio
transitionbio.com

Ampersand Biomedicines
ampersand.bio

Dose Therapeutics

Generate Biomedicines

Convalesce
convalesce.co

MarvelBiome
marvelbiome.com

Intellimedix

PAQ Therapeutics
paqtx.com

Moma Therapeutics

Flare Therapeutics

Enavate Sciences

Frazier Life Sciences

Reset Pharmaceuticals
Companies similar to Faze Medicines include Dewpoint Therapeutics, ProFound Therapeutics, Transition Bio and Ampersand Biomedicines.
Faze Medicines was founded in 2020.
Faze Medicines' headquarters is located in Cambridge, MA, US.
Faze Medicines' most recent funding round was for $81M (USD) in December 2020.
As of Dec 10, 2020, Faze Medicines has raised a total of $81M (USD).
Faze Medicines has 40 employees as of Feb 5, 2024.